patient

Angela Smith, MD, MS

Institution
Children’s Minnesota Hematology Oncology
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pediatric
About
Angela Smith joined the Department of Pediatrics in July 2008 in the Division of Hematology/Oncology/Blood and Marrow Transplantation and became Director of the Division Blood and Marrow Transplantation in 2019. Dr. Smith graduated with her medical degree from the Medical College of Wisconsin in 2002. She then went on to complete her internship and residency in Pediatrics at the University of Minnesota. Following residency, she completed a fellowship in Pediatric Hematology/Oncology/Blood and Marrow Transplantation at the University of Minnesota in June 2008. During her fellowship, she also

Evan Shereck, MD, MEd

Institution
OHSU Hospital
Physician Status
accepting new patients
Primary Disease Area of Focus
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
About
Dr. Shereck specializes in bone marrow transplantation for children with cancer, blood disorders and immunodeficiencies. She conducts clinical trials as a part of the Primary Immune Deficiency Treatment Consortium (PIDTC) and the Pediatric Blood and Marrow Transplant Consortium (PBMTC). Dr. Shereck is also interested in discovering innovative ways to teach the next generation of physicians. She has plenty of opportunities to try out new models of learning through the medical school course she teaches (Blood and Host Defense) and as the fellowship director for pediatric hematology/oncology.

Joshua Sasine, MD, PhD

Institution
Cedars-Sinai
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
Dr. Josh Sasine is a hematologist and oncologist at UCLA specializing in the treatment of hematologic malignancies, including hematopoietic stem cell transplantation (bone marrow transplantation), cellular therapy, and clinical trials of novel therapeutics. He is the Director of the Chimeric Antigen Receptor T-Cell (CAR T) Program. He treats patients with blood and bone marrow disorders such as leukemia, myelodysplastic syndrome, lymphoma, multiple myeloma, amyloidosis, aplastic anemia, Waldenstrom Macroglobulinemia, polycythemia vera, primary myelofibrosis, paroxysmal nocturnal hemoglobinuria

David Sallman, MD

Institution
H. Lee Moffitt Cancer Center & Research Institute
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
Dr. David Sallman is an Assistant Member in the Department of Malignant Hematology at Moffitt Cancer Center. Dr. Sallman’s clinical interests are myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPN). Dr. Sallman earned his MD degree from the University of South Florida College of Medicine. He completed an Internal Medicine Residency at Massachusetts General Hospital and, most recently, a Hematology/Oncology Fellowship at Moffitt Cancer Center. His research interests focus on the development of novel, targeted therapeutic strategies (Phase I and

Michael Pulsipher, MD

Institution
Huntsman Cancer Center, University of Utah
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pediatric

Jeffrey J. Pu, MD, PhD

Institution
SUNY Upstate Medical University
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)

Bhumika Patel, MD

Institution
Prisma Health Cancer Institute - Eastside
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Paroxysmal Nocturnal Hemoglobinuria (PNH)

Mrinal Patnaik, MD, MBBS

Institution
Mayo Clinic Minnesota
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)

Gabrielle Meyers, MD

Institution
OHSU Hospital
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
Dr. Meyers was born and raised in rural Northern California and traveled around the country during her medical training. She developed an interest in hematology and oncology during medical school, and pursued a fellowship in that field after her internal medicine residency. While at the University of Utah, she performed laboratory research on bone marrow failure syndromes, with a focus on paroxysmal nocturnal hemoglobinuria. Her research continues at OHSU, and she currently has government and private foundation support to study the genetic changes that lead to bone marrow dysfunction and

Ruben Mesa, MD, FACP

Institution
Atrium Health Levine Cancer
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
About
Ruben A. Mesa, MD, FACP, is the president and executive director of Atrium Health Levine Cancer and Atrium Health Wake Forest Baptist Comprehensive Cancer Center. He also serves as vice dean for cancer programs and professor of medicine at Wake Forest University School of Medicine. In his roles, Dr. Mesa oversees all efforts related to cancer practice, research and education across the Atrium Health system. Dr. Mesa is an international expert in hematologic cancers. He has dedicated his life's work to research and drug development for myeloproliferative neoplasms (MPNs), a group of chronic

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.